Study protocol
tachycardia, dyspepsia, diarrhea, palpitations, rash, constipation, loss of appetite,, dizziness, headache, hematoma, nausea, vomiting
ADVERSE EFFECTS, HEMATOMA, INJECTION SITE REACTION, LOSS OF APPETITE
All patients were submitted to clinical and anthropometric evaluations, including abdominal circumference (AC), arterial pressure and lab tests, at baseline and after 6 months of protocol. Patients in the treatment group were instructed in the proper daily subcutaneous administration of liraglutide (preferably in the morning, in the abdomen or the upper inner arm) at an initial dose of 0.6 mg/day. The dose was raised by 0.6 mg at weekly intervals until reaching 3 mg/day (0.6 → 1.2 → 1.8 → 2.4 → 3 mg/day). The comparative group received sibutramine at 15 mg/day p.o. in the morning. Patients were monitored for pharmacological tolerance, including adverse effects like nausea, vomiting, diarrhea, constipation, loss of appetite, dyspepsia, sensation of weakness, injection site reactions (hematoma, irritation, rash), dizziness or palpitations, tachycardia, headache, and increased blood pressure. All patients were instructed to reduce their calorie ingestion and to perform 150–300 min of moderately intensive or 75–150 min of vigorous physical activity per week, or an equivalent combination thereof